• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

    12/14/23 8:27:24 AM ET
    $ADBE
    $ASYS
    $AUVI
    $BWV
    Computer Software: Prepackaged Software
    Technology
    Industrial Machinery/Components
    Technology
    Get the next $ADBE alert in real time by email

    Shares of Nxu, Inc. (NASDAQ:NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors.

    Nxu, shares rose 42.1% to $0.0278 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • XBP Europe Holdings, Inc. (NASDAQ:XBP) shares rose 150% to $14.20 in pre-market trading after declining around 20% on Wednesday.
    • Hanryu Holdings, Inc. (NASDAQ:HRYU) gained 34.8% to $1.47 in pre-market trading after jumping 28% on Wednesday.
    • Meiwu Technology Company Limited (NASDAQ:WNW) shares gained 21.1% to $0.0850 in pre-market trading.
    • Codexis, Inc. (NASDAQ:CDXS) shares surged 20.5% to $2.52 in pre-market trading. Codexis announced achievement of gram-scale synthesis with its ECO Synthesis platform.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares climbed 15.2% to $1.74 in pre-market trading. Esperion said that the FDA updated LDL-C lowering indication for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet.
    • Blue Water Biotech, Inc. (NASDAQ:BWV) shares rose 14.9% to $0.3109 in pre-market trading after gaining 7% on Wednesday.
    • Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) gained 14.6% to $1.33 in pre-market trading after falling 15% on Wednesday.
    • Nubia Brand International Corp. (NASDAQ:NUBI) rose 13.8% to $11.00 in pre-market trading after falling 9% on Wednesday.
    • Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares gained 11.1% to $0.19 in pre-market trading.

    Losers

    • Amtech Systems, Inc. (NASDAQ:ASYS) shares fell 26.4% to $4.41 in pre-market trading after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
    • Regis Corporation (NYSE:RGS) shares fell 22.6% to $7.20 in pre-market trading. NYSE will begin delisting proceedings against Regis Corp.
    • Cepton, Inc. (NASDAQ:CPTN) fell 22.4% to $3.08 in pre-market trading after the company posted downbeat third-quarter sales and issued weak FY23 revenue forecast.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) shares fell 18.4% to $1.28 in pre-market trading after jumping 68% on Wednesday.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 18% to $3.23 in pre-market trading. Ocular Therapeutix priced its public offering of 30.8 million common share stock at $3.25 per share for gross proceeds of $100.1 million.
    • Applied UV, Inc. (NASDAQ:AUVI) shares fell 14.5% to $1.59 in pre-market trading after declining around 10% on Wednesday. Applied UV teamed with Silver Cross Hospital in New Lenox, Illinois for the implementation of the groundbreaking Far-UVC Puro Protect 222nm fixtures in the hospital's Sterile Processing Department (SPD).
    • Shattuck Labs, Inc. (NASDAQ:STTK) fell 13.5% to $4.20 in pre-market after gaining 130% on Wednesday. Shattuck Labs announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients.
    • Phio Pharmaceuticals Corp. (NASDAQ:PHIO) fell 11.8% to $0.6873 in pre-market trading after declining 9% on Wednesday. Phio Pharmaceuticals recently announced it will exercise warrants for $2.8 million in gross proceeds.
    • Intensity Therapeutics, Inc. (NASDAQ:INTS) shares fell 8.4% to $9.05 in pre-market trading after jumping 22% on Wednesday. Intensity Therapeutics recently named Joseph Talamo as CFO.
    • Adobe Inc. (NASDAQ:ADBE) fell 6.1% to $586.38 in pre-market trading. Adobe posted upbeat earnings for its fourth quarter, but issued weak sales forecast for full-year 2024.

     

    Now Read This: Lennar Gears Up For Q4 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $ADBE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADBE
    $ASYS
    $AUVI
    $BWV

    CompanyDatePrice TargetRatingAnalyst
    Adobe Inc.
    $ADBE
    9/24/2025$450.00Overweight → Equal-Weight
    Morgan Stanley
    Ocular Therapeutix Inc.
    $OCUL
    9/15/2025$21.00Buy
    Chardan Capital Markets
    Adobe Inc.
    $ADBE
    9/12/2025$450.00 → $405.00Outperform
    BMO Capital Markets
    Shattuck Labs Inc.
    $STTK
    9/8/2025$4.00Outperform
    Wedbush
    Adobe Inc.
    $ADBE
    8/11/2025$310.00Hold → Sell
    Melius
    Adobe Inc.
    $ADBE
    7/2/2025$280.00Neutral → Sell
    Rothschild & Co Redburn
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    Adobe Inc.
    $ADBE
    4/16/2025$495.00 → $450.00Outperform
    BMO Capital Markets
    More analyst ratings

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Esperion to Report Third Quarter 2025 Financial Results on November 6

    ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical comp

    10/23/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Codexis to Report Third Quarter 2025 Financial Results on November 6

    REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 20

    10/23/25 7:05:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the o

    10/21/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, DX Chakravarthy Anil converted options into 1,892 shares and covered exercise/tax liability with 936 shares, increasing direct ownership by 2% to 45,322 units (SEC Form 4)

    4 - ADOBE INC. (0000796343) (Issuer)

    10/16/25 4:37:24 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    EVP & CFO Durn Daniel converted options into 2,832 shares and covered exercise/tax liability with 1,481 shares, increasing direct ownership by 4% to 34,564 units (SEC Form 4)

    4 - ADOBE INC. (0000796343) (Issuer)

    10/16/25 4:37:17 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    SVP & CAO Forusz Jillian converted options into 116 shares and covered exercise/tax liability with 55 shares, increasing direct ownership by 2% to 3,559 units (SEC Form 4)

    4 - ADOBE INC. (0000796343) (Issuer)

    10/16/25 4:37:07 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adobe downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Adobe from Overweight to Equal-Weight and set a new price target of $450.00

    9/24/25 7:54:32 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Chardan Capital Markets initiated coverage on Ocular Therapeutix with a new price target

    Chardan Capital Markets initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $21.00

    9/15/25 8:09:22 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Adobe with a new price target

    BMO Capital Markets reiterated coverage of Adobe with a rating of Outperform and set a new price target of $405.00 from $450.00 previously

    9/12/25 7:47:33 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:50:52 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $227,921 worth of shares (85,000 units at $2.68) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    8/4/25 4:38:06 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $ADBE
    $ASYS
    $AUVI
    $BWV
    SEC Filings

    View All

    Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)

    10/23/25 5:00:24 PM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intensity Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

    10/23/25 4:02:57 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)

    10/9/25 4:30:56 PM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the o

    10/21/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in t

    9/23/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Appoints Craig Thompson to Board of Directors

    ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel

    7/1/25 8:06:21 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Financials

    Live finance-specific insights

    View All

    Esperion to Report Third Quarter 2025 Financial Results on November 6

    ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical comp

    10/23/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Codexis to Report Third Quarter 2025 Financial Results on November 6

    REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 20

    10/23/25 7:05:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Adobe Raises FY25 Digital Media ARR Growth, Total Revenue, and EPS Targets

    Company Reports Record Revenue and RPO Surpasses $20 Billion, Accelerating to 13 Percent Year-Over-Year Growth Adobe (NASDAQ:ADBE) today reported financial results for its third quarter fiscal year 2025 ended Aug. 29, 2025. "Adobe is the leader in the AI creative applications category with AI-influenced ARR surpassing $5 billion and AI-first ARR already exceeding our $250 million year-end target," said Shantanu Narayen, chair and CEO, Adobe. "Given our customer strategy, AI product innovation and strong go-to-market execution, we're pleased to once again raise our FY25 total revenue and EPS targets." "Adobe delivered record Q3 revenue, with strength in subscription revenue across both

    9/11/25 4:05:00 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    11/14/24 3:29:01 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials